B0391 - Efficacy and Safety of Etrolizumab in Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Clinical Trials
Karam R.Motawea, 1, Yomna Ali Abdelghafar, MBBCh2, Yossef Hassan AbdelQadir, MBBCh1, Merna M. Aboelenein, 1, Nancy Ibrahim, MBBCh1, Mohamed Mohamed Belal, MBChB1, Alaa Mahmoud, 3, Ahmed Elsayed, MBChB3, Omar Abdelkader, MBChB3, Ziad Khalifa, MBBCh3, Arinnan Chotwatanapong, MBBCh4, Wangpan Shi, MBBCh5, Sarya Swed, MBChB6, Merna Elsayed, MS7, Ahmed Moursi, MBBCh3, Yousef Tanas, MBBCh1, Yomna E. Dean, MBBCh1, Walaa Hasan, MD3, Hani Aiash, MD, PhD8 1Alexandria University, Alexandria, Al Iskandariyah, Egypt; 2Suez Canal University, Ismailia, As Suways, Egypt; 3Suez Canal University, Ismailia, Al Isma'iliyah, Egypt; 4Chulalongkorn University, Chulalongkorn, Chachoengsao, Thailand; 5Chulalongkorn University, Chulalongkorn, Chaiyaphum, Thailand; 6Aleppo University, Aleppo, Halab, Syria; 7New Giza University, Giza, Al Fayyum, Egypt; 8Upstate Medical University, New York, NY
Introduction: Recent clinical trials have assessed the efficacy and safety of Etrolizumab in treatment of ulcerative colitis.
Aim: To assess the efficacy and safety of Etrolizumab for induction and maintenance of remission in moderate to severe ulcerative colitis.
Methods: We searched the following databases: PUBMED, Web Of Science, OVID, and SCOPUS in 15 January 2022. Inclusion criteria were any phase 2 and 3 clinical trials that compare Etrolizumab with placebo in treatment of moderate to severe ulcerative colitis, excluding case reports, animal studies, phase 1 trials, and conference abstracts. We used RevMan software (5.4) for the meta-analysis.
Results: Five clinical trials were included in our meta-analysis. The total number of patients included in the study is 1249 patients, 960 patients in the Etrolizumab group, and 399 patients in the placebo group. In the induction phase, the pooled analyses showed a statistically significant association between Etrolizumab and increased clinical remission, and endoscopic remission compared with placebo (RR= 2.66, [95% CI= 1.69 to 4.19], P < 0.0001), and (RR= 2.35, [95% CI= 1.52 to 3.65], P = 0.0001). In the maintenance phase, the pooled analyses showed a statistically significant association between Etrolizumab and increased histologic remission and endoscopic remission (RR= 2.04, [95% CI= 1.40 to 2.99], P = 0.0002) and (RR= 1.92, [95% CI= 1.29 to 2.95], P = 0.001). No statistically significant difference was observed in adverse events between Etrolizumab and placebo in induction and maintenance phases.
Discussion: Our results show that Etrolizumab is an effective and safe drug for the induction and maintenance of clinical remission in moderate to severe ulcerative colitis patients proved by histologic and endoscopic findings. Future randomized trials are still needed to compare Etrolizumab to the other agents and further establish its value for the practice.
Disclosures:
Karam R.Motawea indicated no relevant financial relationships.
Yomna Ali Abdelghafar indicated no relevant financial relationships.
Yossef Hassan AbdelQadir indicated no relevant financial relationships.
Merna M. Aboelenein indicated no relevant financial relationships.
Nancy Ibrahim indicated no relevant financial relationships.
Mohamed Mohamed Belal indicated no relevant financial relationships.
Alaa Mahmoud indicated no relevant financial relationships.
Ahmed Elsayed indicated no relevant financial relationships.
Omar Abdelkader indicated no relevant financial relationships.
Ziad Khalifa indicated no relevant financial relationships.
Arinnan Chotwatanapong indicated no relevant financial relationships.
Wangpan Shi indicated no relevant financial relationships.
Sarya Swed indicated no relevant financial relationships.
Merna Elsayed indicated no relevant financial relationships.
Ahmed Moursi indicated no relevant financial relationships.
Yousef Tanas indicated no relevant financial relationships.
Yomna E. Dean indicated no relevant financial relationships.
Walaa Hasan indicated no relevant financial relationships.
Hani Aiash indicated no relevant financial relationships.
Karam R.Motawea, 1, Yomna Ali Abdelghafar, MBBCh2, Yossef Hassan AbdelQadir, MBBCh1, Merna M. Aboelenein, 1, Nancy Ibrahim, MBBCh1, Mohamed Mohamed Belal, MBChB1, Alaa Mahmoud, 3, Ahmed Elsayed, MBChB3, Omar Abdelkader, MBChB3, Ziad Khalifa, MBBCh3, Arinnan Chotwatanapong, MBBCh4, Wangpan Shi, MBBCh5, Sarya Swed, MBChB6, Merna Elsayed, MS7, Ahmed Moursi, MBBCh3, Yousef Tanas, MBBCh1, Yomna E. Dean, MBBCh1, Walaa Hasan, MD3, Hani Aiash, MD, PhD8. B0391 - Efficacy and Safety of Etrolizumab in Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Clinical Trials, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.